Skip to search.
 FTSE 100 Down 0.03%

More On SUMM.L

Quotes

Derivatives

  • Warrants
  • Investment Products

Charts

News & Info

Company

Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates

Ownership

Financials

Summit Therapeutics plc (SUMM.L)

-LSE Ticker: N40HZ0/ISIN: GB00BN40HZ01
128.00 Up 15.50(14.22%) 23 Sep 16:23
Prev Close:112.50
Open:115.00
Bid:N/A x 200000
Ask:N/A x 250000
1y Target Est:N/A
Beta:N/A
Next Earnings Date:N/A
Day's Range:117.00 - 133.75
52wk Range:82.66 - 153.55
Volume:144,454
Avg Vol (3m):36,680
Market Cap:78.70m
P/E (ttm):N/A
EPS (ttm):-0.34
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in GBp.

Headlines

  • No Headlines available for SUMM.L at this time.

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):9,993.82
Ex-Dividend Date:N/A

Analysts

Annual EPS Est () :N/A
Quarterly EPS Est () :N/A
Mean Recommendation*:N/A
PEG Ratio (5 yr expected):N/A

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to treat genetic and infectious diseases in the United Kingdom and North America. more
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback